Gene expression analysis in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R‐apomorphine
暂无分享,去创建一个
[1] Ted M. Dawson,et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.
[2] S. Mandel,et al. The Pivotal Role of Iron in NF‐κB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators , 1999, Annals of the New York Academy of Sciences.
[3] U. Mansmann,et al. Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array , 1999, International journal of cancer.
[4] P. Mecocci,et al. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex , 1999, Neuroscience Letters.
[5] C. K. Lee,et al. Gene expression profile of aging and its retardation by caloric restriction. , 1999, Science.
[6] D. Nebert,et al. Tissue- and cell type-specific expression of cytochrome P450 1A1 and cytochrome P450 1A2 mRNA in the mouse localized in situ hybridization. , 1999, Biochemical Pharmacology.
[7] S. Mandel,et al. Apomorphine protects against MPTP‐induced neurotoxicity in mice , 1999, Movement disorders : official journal of the Movement Disorder Society.
[8] R. Djaldetti,et al. IL-1β, IL-2, IL-6 and TNF-α production by peripheral blood mononuclear cells from patients with Parkinson's disease , 1999 .
[9] Jin Hong Liu,et al. Functional association of TGF-β receptor II with cyclin B , 1999, Oncogene.
[10] A. Ashworth,et al. Structure and chromosomal mapping of the TNF-alpha inducible endothelial protein 1 (Edp1) gene in the mouse. , 1998, Biochimica et biophysica acta.
[11] P. Brown,et al. Drug target validation and identification of secondary drug target effects using DNA microarrays , 1998, Nature Medicine.
[12] R. Klausner,et al. Cell‐cycle arrest and inhibition of G1 cyclin translation by iron in AFT1‐1up yeast , 1998, The EMBO journal.
[13] Zhiming Zhang,et al. Neuroprotective and neurorestorative properties of GDNF , 1998, Annals of neurology.
[14] S H Kim,et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.
[15] S. Hersch,et al. A Human HAP1 Homologue , 1998, The Journal of Biological Chemistry.
[16] I. Nakano,et al. Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1β and nerve growth factor in the striatum , 1998, Neuroscience Letters.
[17] S. Gullans,et al. Characterization of the Hsp110/SSE gene family response to hyperosmolality and other stresses. , 1998, American journal of physiology. Renal physiology.
[18] S. Gullans,et al. Characterization of the Hsp110/SSE gene family response to hyperosmolality and other stresses. , 1998, The American journal of physiology.
[19] P. Jenner,et al. P450 enzymes and Parkinson's disease: The story so far , 1998, Movement disorders : official journal of the Movement Disorder Society.
[20] M. Youdim,et al. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6‐Hydroxydopamine , 1998, Movement disorders : official journal of the Movement Disorder Society.
[21] Y Agid,et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[22] G. Brittenham,et al. Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. , 1997, The American journal of physiology.
[23] R. W. Davis,et al. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[24] H. Yoshida,et al. Low micromolar levels of hydrogen peroxide and proteasome inhibitors induce the 60-kDa A170 stress protein in murine peritoneal macrophages. , 1997, Biochemical and biophysical research communications.
[25] M. Shibutani,et al. Down-regulation of cyclin F levels during nerve growth factor-induced differentiation of PC12 cells. , 1996, Experimental cell research.
[26] M. Youdim,et al. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. , 1996, European journal of pharmacology.
[27] T. Nagatsu,et al. Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease , 1996, Neuroscience Letters.
[28] J. Lile,et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.
[29] P. Baeuerle,et al. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF‐kappa B transcription factor and HIV‐1. , 1991, The EMBO journal.
[30] N. Neff,et al. Epidermal Growth Factor Enhances Striatal Dopaminergic Parameters in the 1‐Methyl‐4‐Phenyl‐l, 2, 3, 6‐Tetrahydropyridine‐Treated Mouse , 1991, Journal of neurochemistry.
[31] Z. Rossetti,et al. The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+) , 1990, Neuroscience Letters.
[32] J. Garthwaite,et al. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. , 1989, European journal of pharmacology.
[33] J. Fujitake,et al. Immunohistochemical evaluation of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons of young adult mice using dopamine and tyrosine hydroxylase antibodies , 1988, Neuroscience Letters.
[34] INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .
[35] K. Jellinger,et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.
[36] A. Bowie,et al. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. , 2000, Biochemical pharmacology.
[37] P. Goodfellow,et al. DNA microarrays in drug discovery and development , 1999, Nature Genetics.
[38] L. Penland,et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.
[39] C. Olanow,et al. Neurodegeneration and Neuroprotection in Parkinson's Disease , 1996 .
[40] S. Wrighton,et al. The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.
[41] K. Jellinger,et al. Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.